NCT05815719View on ClinicalTrials.gov

Continuous Double Ovarian Stimulation.

PHASE4CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

May 30, 2023

Conditions

Fertility Issues

Interventions

DRUG

Corifollitropin Alfa

150 micrograms per dose

DRUG

Follitropin Alfa

Variable dose.

DRUG

Follitropin Alfa Biosimilar

Variable dose.

DRUG

Urinary Human follicle stimulating hormone

Variable dose.

Trial Locations (1)

03016

Instituto Bernabeu, Alicante

Sponsors

Lead Sponsor

Instituto Bernabeu

All Listed Sponsors

lead

Instituto Bernabeu

OTHER